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Tobacco addiction is a major cause of disabilities and premature death. Numerous therapies for de-addiction are available; 
however, nicotine dependence and withdrawal symptoms pose problems for addicts. Here, we developed novel herbal 
formulations using natural plant parts and evaluated for de-addiction of nicotine. Parts of Withania somnifera (L.) Dunal, 
Avena sativa L., Cinnamomum cassia Blume, Acacia catechu (L.f.)Willd., Ocimum tenuiflorum L. and Glycyrrhiza glabra L. 
were formulated in three formulations containing alcohol extracts (AELF), aqueous extracts (WELF) and powdered herbs 
(PHLF). Swiss albino Wistar rats were addicted with nicotine 10 mg/kg/day for first five days and 20 mg/kg/day for next 10 
days subcutaneously. Control rats were administered with 0.9% NaCl (Group VII) and addicted animals were treated with 
bupropion, 40 mg/kg, p.o. (Group I), rid-tobak, 200 mg/kg, p.o. (Group II), AELF, 200 mg/kg, p.o. (Group III), WELF, 200 
mg/kg, p.o. (Group IV), PHLF, 200 mg/kg, p.o. (Group V), 0.5% sodium carboxymethyl cellulose, p.o. (Group VI) for 15 
days. The animals were subjected to Y-maze test, swimming endurance test, behavioural studies on Day 0, 1, 6, 11 and on 
Day 16 after withdrawal of nicotine. On Day16, brain dopamine and serum cortisol levels were measured. Rats treated with 
AELF and PHLF showed significant improvement in behavioural parameters, increased brain dopamine level and decreased 
serum cortisol levels thus being a promising choice for tobacco cessation. 
Keywords: Ashwagandha, Avena sativa, Chinese cassia, Cinnamon, Cutch tree, Glycyrrhiza glabra, Herbal formulation,  
Holi basil, Indian ginseng, Liquorice, Nicotiana tabacum, Oat, Tobacco de-addiction, Tulsi, Withania somnifera 
Human beings commonly get addicted to pyridine 
alkaloids of tobacco than to any other naturally 
occurring plant products. Tobacco (Nicotiana tabacum, 
Fam.: Solanaceae) addicts exist in almost all classes 
of the society; while in most of the cases only alcohol 
rehabilitation campaigns in world are running1. In 
India, more than 42.4% of males, 14.2% females and 
14.6% of children (<15 yr) are addicted to tobacco2. 
Addiction, according to World Health Organization, is 
a state of periodic or chronic intoxication characterized 
by first tolerance, craving and finally dependence of 
that substance produced by its repeated consumption3. 
 
Tobacco rehabilitation campaign is slow and very 
few de-addiction therapies4 are available and are often 
expensive5. The nicotine replacement therapy products 
require long term therapy and have side effects6. We 
hypothesize that, the formulation developed for 
nicotine cessation, should have ability to compensate 
dopamine levels in brain. It should help in minimizing 
abstinence syndromes as well as reduce harmful effects 
of tobacco. It should have anti stress, anxiolytic, anti-
psychotic, anti-oxidant, nervine tonic effects, etc7.  
 
The present study, attempts to design formulations 
depending upon the pharmacological effectiveness of 
herbs for tobacco cessation. The herbs have been 
selected based either on reports for smoking cessation 
effects8 or those herbs which help in relaxing the 
affected area in brain or for their tonic and 
strengthening effects on the physiological system9. 
Thus, the main objective of the study is to develop a 
polyherbal formulation and evaluate it for tobacco 
cessation in nicotine addiction rat model for  
de-addiction properties. 
 
Materials and Methods  
Dried roots of Withania somnifera (L.) Dunal, 
Glycyrrhiza glabra L. stolons, Ocimum tenuiflorum L. 
—————— 
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(syn. Ocimum sanctum) leaves, Acacia catechu (L.f.)Willd. 
extract, Cinnamon cassia Blume bark and Avena sativa L. 
seeds were purchased from ACS Chemicals, Ahmedabad 
and got authenticated at Raw Materials, Herbarium and 
Museum, Delhi (RHMD) CSIR-NISCAIR, New Delhi. 
L-Nicotine (99% of assay purity) was purchased from 
ACROS Organicals Ltd., India; Bupropion hydrochloride 
from SIGMA Organicals and Chemicals Ltd. ‘Rid 
tobak’ antismoking mouth drops was purchased from 
local drug store. Dopamine estimation Kit was 
purchased from LABOR Diagnostic Nord GmbH & Co. 
KG (Germany), Serum cortisol level (ADVIA Centaur 
Assay) estimation kit was obtained from Sigma 
Diagnostic Kit, Sigma-Aldrich Corp., St. Louis, MO. 
All the solvents used were of Analytical grade, 
purchased from Qualigens, Mumbai, India. 
 
Method of preparation 
Withania somnifera (8 parts), G. glabra (6 parts),  
O. tenuiflorum (6 parts), A. catechu (4 parts), C. cassia  
(3 parts) and A. sativa (3 parts) were selected for 
preparing the formulation. All the crude drugs were 
pulverized and passed through sieve 80 mesh. Three 
formulations were prepared using the alcohol extracts 
(AELF), water extracts (WELF) and powdered crude 
drug (PHLF). The extracts were prepared using 
soxhlation and concentrated using rotary evaporator, 
and then dried at room temperature (25C) in 
desiccators10. The extracts were weighed and mixed 
together. The formula was prepared under the guidance 
of experienced doctors of Indian Medicine and as per 
reported literature8.  
The PHLF was prepared from powdered plants 
using ‘rolling between palm’ method with 20% 
hydroalcoholic gum solution11. Similarly, AELF and 
WELF were also prepared from ethanol and aqueous 
extracts, respectively and ‘rolling between palm’ 
method using 20% hydroalcoholic gum solution. 
 
Animals  
Female Balb/c mice weighing between 20-25 g and 
adult female Swiss albino rats of Wistar strain having 
average body weight between 160 and 200 g were 
housed for at least 5 days before being used in a room 
with controlled temperature (23±1C), humidity 
(50±10%) and light (6.00 a.m. to 6.00 p.m.). Food and 
water were made available continuously. Animal care 
and use for experimental procedures were approved by 
the Institutional animal care and use committee. All 
anaesthetic and other procedures were in compliance 
with the guidelines established by the Animal Care 
Committee (Pharmacy Department, M. S. University, 
Baroda/404/01/1/CPCSEA). All behavioural parameters 
were studied during the light phase of the cycle.  
 
Acute toxicity of formulations 
Acute Toxicity study of formulations was carried 
out as per the OECD guidelines12. Female Balb/c mice 
weighing between 20-25 g were administered orally 
with single dose of 2000, 1550, 550, 175,  
55 mg/kg of formulations after overnight fasting. The 
animals were kept under observation for 12 h for any 
signs of abnormal behaviour or symptoms and for 
seven days for any mortality or abnormality. 
 
Effect of formulation on nicotine addicted rats 
Nicotine habituation13 was induced in Group I to VI by 
injecting nicotine s.c. 10 mg/kg per day for first  
5 days and 20 mg/kg per day for next 10 days. 
Treatments were given simultaneously as; Group I 
(bupropion, 40 mg/kg, p.o.), Group-II (rid-tobak,  
200 mg/kg, p.o.), Group-III (AELF, 200 mg/kg, p.o.), 
Group-IV (WELF, 200 mg/kg, p.o.), Group-V (PHLF, 
200 mg/kg, p.o.), Group-VI (0.5% sodium carboxy 
methyl cellulose, p.o.) and Group VII (Normal), were 
dosed 0.9% NaCl (normal saline) (s.c.) for all 15 days. 
Study formulations were administered to rats from  
Day 1 to Day 16, one hour before nicotine 
administration. Behavioural tests were performed on 
Day 0, 1, 6, 11 and 16 (the day of nicotine withdrawal). 
AELF, WELF and PHLF were dissolved in 0.5% 
sodium carboxy methyl cellulose, p.o. in distilled water 
vehicle.  
 
Behavioural studies 
All behavioural parameters were studied in dark and 
silent room. Details of tests performed are given below. 
 
Y-maze test  
Y-maze test was performed 15 min after acute 
administration of nicotine or saline to the rats14.  
The light of 10 watts was used to enlighten the light 
arm, Exposure time for test was 5 min. Each rat was 
placed at the centre of a Y-shaped wooden runway  
(Y maze, YM; 65×45× 35 cm) with one of the three 
arms closed. The percentage cumulative time spent by 
the rat in the open arm, the latency period when the 
animal remains immobile and the number of visits in 
each arm was recorded for 5 min15. 
 
Tail immersion test  
The test was performed on the same rats after  
Y-maze test. The time of flicking of rat tail  
was measured in seconds with a cut off latency of  
10 s, to prevent tissue damage16.  
GADHVI et al.: POLYHERBAL FORMULATION FOR TOBACCO DE-ADDICTION 
 
 
383 
Swimming endurance test  
This test was performed after 35 min of nicotine 
administration or withdrawal17. The dimensions of test 
apparatus were 55 cm diameter and 60 cm depth18. A 
weight of 7% of rat body weight was tied on rat’s tail 
and made to swim until they start sinking19. The 
swimming time was recorded in min. The water 
temperature was maintained at 50±0.5C. 
 
Somatic signs  
Nicotine abstinence syndromes were observed and 
measured on Day 16 of treatment20. Signs like sniffing, 
rearing, teeth chattering, backing, nibbling, noisy 
respiration, climbing, scratching and head shaking 
were measured in occurrence per min21.  
 
Preparation of brain homogenate  
On day 16, the rats were decapitated after 4 hours of 
withdrawal, brains removed, washed in pre-chilled 
normal saline and homogenized in an isotonic pre-
chilled Tris HCl buffer (7.4 pH) with a glass 
homogenizer at 1000 rpm. The homogenized brain was 
used for dopamine estimation22.  
 
Estimation of brain dopamine in rat 
Dopamine was extracted using a cis-diol-specific 
affinity gel and then acylated to N-acyldopamine and 
after this converted enzymatically during the detection 
procedure into N-acyl-3-methoxytyramine23. The 
competitive EIA kit was based on the microtiter plate 
format24. About 100 µL of the extracted standards and 
samples were transferred to the appropriate wells and 
incubated for 30 min at room temperature on a shaker 
set at 400-500 rpm. About 50 µL of dopamine 
antiserum was added into all wells and incubated for 2 h 
at room temperature on an orbital shaker (400-500 rpm). 
The contents of the wells were aspirated, discarded and 
washed thoroughly with 300 µL diluted wash buffer. 
This process was done twice. It was blotted dry by 
inverting plate on absorbent material. About 100 µL of 
the enzyme conjugate was transferred into all wells and 
incubated for 30 min at room temperature on an orbital 
shaker (400-500 rpm)25. Again, the aspirates were 
collected and rest of the samples were discarded and 
washed thrice. About 100 µL of substrate was 
transferred into wells and incubated for 20-30 min at 
room temperature on an orbital shaker (400-500 rpm). 
Then, 100 µL of the stop solution was added to each 
well and the micro titre plate was shaken to ensure a 
homogeneous distribution of the solution. The 
absorbance of the solution in the wells was observed 
within 10 min, using a micro plate reader set to a 
reference wavelength between 450 and 630 nm. The 
amount of antibody bound to the solid phase dopamine 
is inversely proportional to the dopamine concentration 
of the sample26.  
 
Estimation of serum cortisol in rat  
Female albino rats were incised by aseptic surgical 
blade at the neck aorta portion and then bled. The blood 
was collected in a polypropylene container. Serum was 
isolated by centrifugation at 8000 rpm. About 20 µL of 
sample was dispensed in to a cuvette followed by  
50 µL of Lite Reagent and 250 µL of solid phase and 
incubated for 5 min at 37C. The aspirates were 
separated and the cuvettes washed with reagent water. 
Later, 300 µL each of acid reagent and base reagent 
were added to initiate the chemiluminescent reaction, 
and the readings were taken27. 
 
Statistical analysis 
The mean ± SEM values were calculated for each 
group. For determining significance of intergroup 
difference, each parameter was analyzed separately by 
using one-way ANOVA. Student t test was also applied 
to detect ‘p’ value of P <0.05 was considered to be the 
level of significance28.  
 
Results  
 
Acute toxicity studies 
In the acute toxicity study, all three formulations up 
to the dose level of 2000 mg/kg of body wt. did not 
exhibit any lethality or toxic symptoms. As per the 
OECD guidelines, these formulations were found to be 
safe and well tolerated without any behavioural 
changes during study. 
 
Behavioural studies 
 
Y-maze study 
Latency period in each arm was noted, it is the time 
span in which an animal remains in immobile state. 
Less latency time indicates anxious state of brain. The 
histogram (Fig. 1) of Day 1 indicates that rats remained 
more immobile in dark arm. But during addiction i.e. 
at day 6 latency in dark arm reduces but on Day 16  
(the day of nicotine withdrawal) the negative control 
group has highest latency in the dark arm. The 
treatment groups like market formulation and PHLF 
treated groups significantly reduced the latency 
compared to negative control i.e. the formulations 
proved to be good in reducing anxiety at the time of 
withdrawal. The studies were performed to assess 
effect of treatment on latency effect of nicotine. 
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More the visits in dark arm and less or no visit in 
lighted arm indicate the depressed state of brain. More the 
visits in every arm indicate the anxious state of mind. Fig. 
2 (6th day) depicts decrease in total visits of all groups in 
all arms compared to normal Group VII. However, all 
groups except positive control and AELF treated group 
showed increased visits on 16th day of nicotine 
withdrawal (Fig 2) than the normal group. 
On day 6 after nicotine treatment, time spent in light 
arm had decreased (Fig. 3) compared to day 1 (without 
nicotine treatment). At Day 11, AELF treated and 
bupropion treated group have significantly increased time 
spent in light arm. PHLF treatment has decreased time 
spent in dark arm (Fig. 3).  
 
Tail immersion study 
Nicotine produces analgesia within 5 min of 
subcutaneous administration in rats. During nicotine 
withdrawal  period,  the  potentiating effect of nicotine 
induced analgesia would be diminished. Rats of all 
groups showed significant increase in tail flick time 
compared to normal group after nicotine treatment 
depicting the effect of nicotine as an analgesic. On 6 
and 11 days of AELF treatment significantly reduced 
the analgesic effect of nicotine than nicotine control 
group (Fig. 4). There was no effect of nicotine with-
drawal on the tail flick time when compared with 1st day. 
 
 
 
 
Fig. 1 — Latency period (A-D: Days 1, 6, 11 & 16, respectively) in each arm. [1.0, Open arm; 2.0, Dark arm; 3.0, Light arm. Groups: I, 
bupropion @ 40 mg/kg, p.o.; II, rid-tobak @ 200 mg/kg, p.o.; III, AELF, @ 200 mg/kg, p.o.; IV, WELF @ 200 mg/kg, p.o.; V, PHLF  
@ 200 mg/kg, p.o.; VI, 0.5% sodium carboxy methyl cellulose, p.o.; and VII, normal saline (0.9% NaCl)] 
 
 
 
Fig. 2 — Number of visits on (A-D: Days 1, 6, 11 & 16, respectively) in each arm. [1.0, Open arm; 2.0, Dark arm; 3.0, Light arm. Groups: 
I, bupropion @ 40 mg/kg, p.o.; II, rid-tobak @ 200 mg/kg, p.o.; III, AELF, @ 200 mg/kg, p.o.; IV, WELF @ 200 mg/kg, p.o.; V, PHLF 
@ 200 mg/kg, p.o.; VI, 0.5% sodium carboxy methyl cellulose, p.o.; and VII, normal saline (0.9% NaCl)] 
 
 
 
Fig. 3 — Total time spent on day 1, 11, 16 & 16 (A-D) in each arm. [1.0, Open arm; 2.0, Dark arm; 3.0, Light arm. Groups: I, bupropion 
@ 40 mg/kg, p.o.; II, rid-tobak @ 200 mg/kg, p.o.; III, AELF, @ 200 mg/kg, p.o.; IV, WELF @ 200 mg/kg, p.o.; V, PHLF @ 200 mg/kg, 
p.o.; VI, 0.5% sodium carboxy methyl cellulose, p.o.; and VII, normal saline (0.9% NaCl)] 
 
 
 
 
Fig. 4 — Tail flick time observed on day 1, 6, 11 and 16 of tail 
immersion study. [* compared to control, and # nicotine treated group] 
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Swimming endurance test 
Nicotine reduces swimming time which is visible in 
nicotine control group at 11th day (Fig. 5). All groups 
except normal group have shown decrease in 
swimming time after nicotine injection. There is no 
effect of nicotine withdrawal on swimming 
performance. AELF treatment has increased the 
swimming time than nicotine control significantly at  
6th day. All treatments did not have significant effect 
on swimming performance after nicotine treatment.  
 
Nicotine abstinence study 
In the nicotine control group, the withdrawal signs 
observed were exaggerated significantly as compared 
to the normal group on the 16th day (Table 1, & Fig. 6). 
Significant reduction in the nicotine withdrawal 
syndromes was observed in AELF treated rats when 
compared with the significantly from nicotine control 
group.  
 
Effect on brain dopamine level 
Dopamine measurement was performed after 24 h 
of nicotine withdrawal there was reduction in 
dopamine release when nicotine is suddenly 
withdrawn. From the graph nicotine control group rats 
were showing less dopamine content than normal 
group rats. PHLF, AELF and Market formulation 
treatment have significantly maintained the dopamine 
compared to nicotine control group (Fig. 7).  
 
Effect on serum cortisol  
Bupropion, market formulation and PHLF treatment 
significantly reduced the cortisol level compared to 
 
 
 
Fig.6 — Nicotine withdrawal syndrome on day 16th of study. [* compared to normal control, and # nicotine treated group] 
 
Table 1 — Nicotine abstinence syndrome on Day 16 (the day of withdrawal) 
Nicotine Abstinence Signs 
Group Sniffing Teeth chattering Head shaking Scratching Climbing Nibbling Noisy respiration Backing 
I 3.0±0.4 3.0±0.33 2.0±0.3## 3.0±0.2## 2.0±0.1 2.0±0.5 4.0±0.2 0.0±0.1## 
II 4.0±0.1 3.0±0.2 2.0±0.2 4.0±0.1 0.5±0.1## 4.0±0.25 3.0±0.2 0.0±0.1 
III 2.0±0.3# 2.0±0.24# 3.0±0.3 3.0±0.2## 0.5±0.1## 3.0±0.1## 2.0±0.1## 0.0±0.1 
IV 3.0±0.13 3.0±0.2 4.0±0.2 4.0±0.15 3.0±0.1 4.0±0.1 4.0±0.2 0.0±0.2# 
V 3.0±0.1 3.0±0.05 3.0±0.11 4.0±0.1 3.0±0.21 3.0±0.1## 3.0±0.08 0.0±0.05 
VI 8.0±0.1** 5.0±0.08* 6.0±0.1** 8.0±0.14** 8.0±0.2** 9.0±0.1** 6.0±0.05* 2.0±0.02** 
VII 2.0±0.1 1.0±0.2 2.0±0.12 1.0±0.15 0.1±0.25 2.0±0.1 3.0±0.2 0.0±0.02 
[Each column represents the mean ± S.E.M. (n=6). # P <0.05, ## P <0.01, ### P <0.001 as compared to nicotine treated group.  
* P <0.05, ** P <0.01, *** P <0.001 as compared to normal group] 
 
 
 
 
Fig. 5 — Swimming time (min) observed on day 1st, 6th, 11th and 
16th day of the swimming endurance study. [* compared to control, 
and # nicotine treated group] 
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nicotine control group during nicotine withdrawal as 
shown in Fig. 7B. 
 
Discussion 
Nicotine dependence was induced successfully in 
mice and on 16th day, significant withdrawal symptoms 
were observed in comparison to the control group. 
Nicotine binds to the neurons in certain areas of the 
brain, on consumption of tobacco, which quickly 
secrete some dopamine, which acts on the “reward” 
areas of the brain and is perceived as very pleasurable. 
But the receptors on these cells lose their sensitivity to 
nicotine in a short time, mere seconds to a few min, and 
the cells stop secreting dopamine. As it turns out, this 
same type of receptor for nicotine also occurs on pre-
synaptic terminals in this same area of the brain which 
are activated by nicotine. This leads to the release of a 
signal molecule, glutamine, which acts on certain 
dopaminergic neurons to stimulate them to release 
more dopamine. This activation results in continued 
release of dopamine for hours, a case of long-term 
potentiation of excitatory input. The whole mechanism 
is similar to events seen during learning and memory 
and may be an important early step in the development 
of addiction2. 
 
Prepared novel tobacco cessation formulations 
showed their efficacy in many ways in comparison 
with marketed herbal formulation and allopathic 
molecule i.e. bupropion treatments. AELF and PHLF 
treatment results have proved to be effective to reduce 
the nicotine craving by maintaining the dopamine level 
in brain and reducing cortisol level in serum. 
Therefore, AELF and PHLF were found to be potent 
for nicotine cessation29. The herbs incorporated in the 
formulations, for example, W. somnifera contain some 
major active constituents such as withanolide A, 
withanoside IV and withanoside VI30. These compounds 
have GABA mimetic and acetyl cholinesterase 
activity. The aqueous and alcoholic extracts of this 
plant have been proved to be effective in alcohol 
withdrawal induced anxiety and convulsions in mice. 
Studies have reported that 1.0 μM doses of each 
compound produces significant neurite outgrowth in 
dopaminergic SH-SY5Y cells. They have also been 
used traditionally to protect health of mind and body as 
an adaptogenic, rejuvenative, anti-inflammatory and 
antistress31. Studies have proved the effect of Withania 
somnifera in conditions of stress, fatigue, mood swings 
and weakness due to disease or drug withdrawal32. It 
helps to restore mental and physical vitality and 
adaptability33. Ocimum tenuiflorum has been reported 
to show antistress activity in despair swim test model 
of mice34. It is also reported to treat the respiratory tract 
problems and thus the issues related to nicotine 
withdrawal like coughing and sore throat can be 
eliminated35.  
 
Chronic constipation and intestinal cramps are the 
major withdrawal symptoms showing physical 
dependence and A. catechu has been used traditionally 
for treatment of digestive problems like constipation36. 
Cinnamomum zeylanicum has been reported to make 
the taste of tobacco unpalatable thus reducing the 
craving for nicotine37. Avena sativa has been reported 
to reduce the pressor response produced by nicotine in 
anesthetized rat38. It is also reported to be a nervine 
tonic. Glycyrrhiza glabra has been well studied for its 
effect on norepinephrine and dopamine leading to an 
anti-depressant activity39,40. Bupropion, a nor-
epinephrine-dopamine re-uptake inhibitor has been 
used extensively as one of the drugs in smoking 
cessation41. However, it has been reported to have 
numerous side effects like epileptic seizures, nausea, 
headache, etc.42.  
 
Conclusion 
In this study, we made an attempt to develop a 
polyherbal formulation using parts of Ashwagandha or 
Indian ginseng (Withania somnifera), Oat (Avena 
sativa), Cinnamon (Cinnamomum cassia), Cutch tree 
(Acacia catechu), Tulsi (Ocimum tenuiflorum) and 
Liquorice (Glycyrrhiza glabra) for tobacco addictive 
patients. The results of behavioural studies and 
biochemical markers showed that the formulation 
 
 
 
Fig. 7 — (A) Brain dopamine levels (µg/g); and (B) serum cortisol level 
(µg/dL) in rat brain on day 16. [* compared to normal, and # nicotine 
treated group] 
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AELF (alcoholic extract) and PHLF (powdered crude 
drug) have significantly reduced the nicotine 
abstinence symptoms, stress and cortisol levels and 
managed to maintain the brain dopamine levels in rats. 
The present study performed in rats induced with 
nicotine dependence, proposes the option of using 
AELF and PHLF formulations for nicotine de-
addiction as well as for treatment of mental and 
physical withdrawal symptoms. The two formulae, 
AELF and PHLF should be studied further to 
determine the dose dependent efficacy followed by 
clinical studies.  
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